Company
Taiho Oncology
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
3
3 still marketed
Novel approvals
3
Approvals since 2021
3
Originals and new uses
Phase 3 trials
10
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Inqovi new use OrphanMay 13, 2026
- Lonsurf new use Priority reviewOrphanAug 2, 2023
- Lytgobi approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanSep 30, 2022
- Inqovi approved NovelPriority reviewOrphanJul 7, 2020
- Lonsurf new use Priority reviewOrphanFeb 22, 2019
- Lonsurf approved NovelOrphanSep 22, 2015
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionPivotal-lookingRecruiting
Taiho Oncology, Inc.Industry
NCT07128199 · 360 participants (planned) · Start Dec 22, 2025 · Primary completion Oct 1, 2029
Drug: TAS6417; Zipalertinib Matching-placebo · For: Lung Cancer; Adjuvant; Post-surgical and 5 more
Sites: Anchorage, Alaska; Duarte, California; Irvine, California · 253 sites in all
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)Pivotal-lookingRecruiting
Taiho Oncology, Inc.Industry
NCT04256317 · 316 participants (planned) · Start May 21, 2020 · Primary completion Nov 1, 2027
Drug: Azacitidine; ASTX030 (cedazuridine + azacitidine) and 4 more · For: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myelodysplastic Syndrome/Neoplasm and 1 more
Sites: Los Angeles, California; Orange, California; New Haven, Connecticut · 73 sites in all
Marketed drugs (3)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.